Select Bibliography

Filter by any of these (after searching):

C9581

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 8 items

Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581

Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary - Primary - GI - C9581

Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803

Bertagnolli, Monica M. , Redston, Mark , Compton, Carolyn C. ... - - J Clin Oncol - 2011

Manuscript - Primary - Primary - GI - C150705 , C89803 , C9581

Endpoints for validation of tumor markers for recurrence risk: Recurrence-free interval (RFI), disease-free survival (DFS), overall survival (OS), and colon-cancer specific survival (CCSS) in CALGB 9581

Mahmoud, N. N. , Lopatin, M. , Lee, M. , Clark-Langone, K. ... - - Eur. J. Cancer - 2011

Abstract - Secondary - Primary - GI - C9581

Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581

Niedzwiecki, Donna , Bertagnolli, Monica M. , Warren, Robert S. ... - - J Clin Oncol - 2011

Manuscript - Primary - Primary - GI - C9581

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)

Niedzwiecki, Donna , Frankel, Wendy L. , Venook, Alan P. , Ye, Xing ... - - J. Clin. Oncol - 2016

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150705 , C9581

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803

Niedzwiecki, Donna , Hasson, Rian M. , Lenz, Heinz‐Josef ... - - Oncologist - 2017

Manuscript - Secondary-not-in-original - Meta-Analysis - GI - C89803 , C9581

Validation of a 12-gene colon cancer recurrence score (RS) in stage II colon cancer (CC) patients (pts) from CALGB 9581

Venook, A. P. , Niedzwiecki, D. , Lopatin, M. , Lee, M. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary - Primary - GI - C9581

Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581

Venook, Alan P. , Niedzwiecki, Donna , Lopatin, Margarita , Ye, Xing ... - - J. Clin. Oncol. - 2013

Manuscript - Secondary - Primary - GI - C9581 , C150705